Robert's Two-Week Audition: The Mets' Trade Calculus and the Injury Risk Premium

The Mets reinstated Luis Robert Jr. from the 60-day injured list on Monday, July 21, ending a three-month absence stemming from disc inflammation in his lower back. Per Ken Rosenthal and Will Sammon of The Athletic, the team is already fielding preliminary trade interest in the 27-year-old center fielder—a signal that New York sees him as a potential trade chip rather than a cornerstone of their long-term plans. The timing is no accident: Robert has roughly 12 days to demonstrate that his back can sustain a full workload before the August 3 trade deadline arrives.

Robert's injury history carries real weight in any trade negotiation. A player returning from a three-month soft-tissue absence in the spine enters the market with an implicit health warranty attached. Buyers will demand assurances that the inflammation has genuinely resolved and that game action won't trigger a recurrence that could sideline him for another six weeks. The Mets, having already absorbed the cost of Robert's lost plate appearances, have incentive to move him before the deadline if the medical clearance holds. But any acquiring team will price in the risk that Robert could land back on the IL within 30 days of arrival.

For betting purposes, this creates two distinct windows. Over the next 12 days—through early August—Robert's at-bat total, hit total, and RBI props should trade at a discount to his talent level, because his workload is almost certainly being managed. Expect limited starts, pinch-hit duty, and conservative rest days while the team courts trade partners and gauges his durability. The market may price his prop lines as if he's a full-time contributor; the reality is closer to a part-timer getting 3–4 at-bats per game. After August 3, if he clears waivers and remains a Met, or if he lands on a new team with a clean bill of health, his prop pricing will reset higher. The short-term edge belongs to unders on his offensive volume.

The trade interest itself is a valuation tell. The Mets wouldn't be taking calls if they believed Robert could be a 40-home-run center fielder for them in 2027 and beyond. Instead, the front office is acknowledging that the back injury has created doubt—both internal and external—about his durability as a full-time starter. Any team that acquires him is buying low on talent but pricing in the probability of future missed time. For bettors, this means Robert's props are likely overweighting his baseline talent and underweighting the practical ramp-up period he's about to enter.